Annals of internal medicine
-
Comment
In CKD, the effect of dapagliflozin on kidney outcomes did not vary by T2DM status or CKD cause.
Wheeler DC, Stefánsson BV, Jongs N, et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9:22-31. 33338413.
-
This commentary discusses the interplay of pregnancy and SARS-CoV-2 infection. The authors explain why COVID-19 vaccination efforts should not exclude pregnant women.